Infectious diseases include a diverse array of disorders caused by viruses, bacteria, fungi, or parasites. The need to develop new drugs targeting infectious diseases has never been greater due to the rise of microbial and bacterial resistance.
In 2013, the Centers for Disease Control and Prevention (CDC) estimated that each year approximately two million people in the US are infected with resistant bacterial infections, resulting in around 23,000 deaths.
There are a number of challenges with developing infectious disease drugs. Experience in the field has highlighted the critical nature of clinical trial design and the role that pharmacokinetics can play in guiding appropriate clinical dosing. Modeling and simulation is often essential for devising optimal dosing strategies.
Nuventra’s vast experience with infectious disease has enabled our clients to make well-informed decisions about their development programs. Our scientist’s wealth of knowledge has facilitated rapid and efficient analyses and interpretations of pharmacokinetic and pharmacodynamic data for infectious diseases.
Nuventra’s Infectious Disease Experience
Nuventra can perform any of our wide range of services for drugs to treat Infectious Disease indications.
Visit our services page to see our full range of services and to learn more about what our drug development consultants can offer your program.
Infectious Diseases Indications
Nuventra has experience with a number of Infectious Diseases indications, including:
- Candida Species
- Dermatophytic Fungi
- Ebola Virus
- Hepatitis C Virus
- Human Immunodeficiency Virus
- Influenza Virus
- Lyme Disease
- Marburg Virus